Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
ELREXFIO: selected primary-label renal guidance and limits
Product / population
Adult ELREXFIO subcutaneous therapy for its labeled myeloma setting; not a complete treatment or step-up regimen.
Renal method
MDRD eGFR, mL/min as printed
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
ELREXFIO: source applicability and renal evidence limits
Severe impairment and ESRD effects unknown; no dialysis regimen established. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Retain the exact product step-up and safety monitoring requirements.
DailyMed / product prescribing information · Adult ELREXFIO subcutaneous therapy for its labeled myeloma setting; not a complete treatment or step-up regimen.
Renal method: MDRD eGFR, mL/min as printed Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
Severe impairment and ESRD effects unknown; no dialysis regimen established.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3, Specific Populations
PK was not meaningfully different with eGFR 30-89. Effects at eGFR 15-29 and <15 mL/min are unknown. This PK-only statement does not provide a new renal-dose schedule. Follow the product-specific step-up, cytokine-release/neurotoxicity and infection precautions independently.
RDM72-elranatamab-elrexfio-label-1 · Source locator: Section 12.3, Specific Populations
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
